ClinicalTrials.gg

Program

tesamorelin

Also written as “Tesamorelin” and “TH9507”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · HIV-Associated Lipodystrophy Syndrome · Pulmonary Disease, Chronic Obstructive · Diabetic Retinopathy · HIV Infections, led by 2 companies.

Furthest: phase 4, since May 2, 20127 company-led studies, 1 open or runningNext primary completion: Feb 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Theratechnologies60 open or runningphase 4since May 2, 2012Jul 20, 2005none ahead
Hudson Biotech11 open or runningphase 2since Mar 8, 2026Mar 8, 2026Feb 14, 2027phase 2 · NCT07481734

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2005First study: phase 3 study in HIV InfectionsNew to TheratechnologiesTheratechnologies · NCT00123253 · 412 enrolled · United States, Canada
  2. Jan 23, 2008Phase 3 study in LipodystrophyTheratechnologies · NCT00608023 · 263 enrolled · United States, Belgium, Canada and more
  3. Dec 17, 2010Phase 2 study in Diabetes Mellitus, Type 2Theratechnologies · NCT01264497 · 55 enrolled
  4. Jul 5, 2011Phase 2 study in Pulmonary Disease, Chronic ObstructiveTheratechnologies · NCT01388920 · 3 enrolled
  5. May 2, 2012Phase 4 study in Diabetic RetinopathyTheratechnologies · NCT01591902 · 129 enrolled · United States
  6. Nov 26, 2013Phase 1 study in HIVTheratechnologies · NCT02012556 · 18 enrolled · Canada
  7. Mar 8, 2026Hudson Biotech's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Hudson BiotechHudson Biotech · NCT07481734 · 120 planned · China

Ahead

  1. Feb 14, 2027Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseHudson Biotech · NCT07481734

TargetBeta

GHRHR →read by rule
“Growth hormone-releasing hormone receptor agonist”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07481734Non-alcoholic Fatty Liver Disease · China2RecruitingHudson BiotechFeb 14, 2027120
NCT02012556HIV · Canada1CompletedTheratechnologiesJul 200818
NCT01591902Diabetic Retinopathy · United States4TerminatedTheratechnologiesMay 2018129
NCT01388920Pulmonary Disease, Chronic Obstructive2TerminatedTheratechnologiesDec 20113
NCT01264497Diabetes Mellitus, Type 22CompletedTheratechnologiesNov 200255
NCT00608023Lipodystrophy · United States, Belgium, Canada and more3CompletedTheratechnologiesOct 2008263
NCT00123253HIV Infections · United States, Canada3CompletedTheratechnologiesNov 2006412

How it is read

Names in the registry

  • “Tesamorelin”, 5 entries
  • “TH9507”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.